Kolexia
Petorin Caroline Médecine interne
Petorin Caroline
Médecine interne
Hôpital Estaing
Clermont-Ferrand, France
50 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Tumeurs du pancréas Neuropathies périphériques Tumeurs neuroendocrines Tumeurs gastro-intestinales Syndromes neurotoxiques Tumeurs du foie Carcinome neuroendocrine

Collaborateurs

Voir plus
Pezet Denis
Pezet Denis
Hôpital Estaing, Clermont-Ferrand, France
Phelip Jean-Marc
Phelip Jean-Marc
Hôpital Nord CHU Saint-Étienne - Loire, Saint-Priest-en-Jarez, France
Lepage Come
Lepage Come
Hôpital François Mitterrand, Dijon, France
Walter Thomas
Walter Thomas
Hôpital Edouard Herriot, Lyon, France

Industries

Voir plus
Ipsen
5 collaboration(s)
Dernière en 2021
Advanced Accelerator Applications
3 collaboration(s)
Dernière en 2022
Sanofi
2 collaboration(s)
Dernière en 2021
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Cancer chemotherapy and pharmacology   07 novembre 2023
PROPERTY: Randomized, Double-blind, Multicenter Placebo-controlled Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy
Essai Clinique (Algosource)   05 octobre 2023
LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy.
Trials   20 janvier 2023
REMINET: A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   21 décembre 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
European journal of cancer (Oxford, England : 1990)   07 septembre 2022
PANOPTIMOX: Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   18 août 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Endocrine-related cancer   17 août 2022